Paper - WANFANG MED ONLINE

You Position: Home > Paper

Molecular diagnosis and treatment of meningiomas: an expert consensus (2022)

( views:8, downloads:1 )

Author:: No author available

Journal Title:: Chinese Medical Journal

Issue:: 16

DOI:: 10.1097/CM9.0000000000002391

Key Word:: Clinical diagnosis;Expert consensus;Meningioma;Molecular subtyping;Therapeutic treatment;Clinical diagnosis;Expert consensus;Meningioma;Molecular subtyping;Therapeutic treatment

Abstract： Meningiomas are the most common primary intracranial neoplasm with diverse pathological types and complicated clinical manifestations. The fifth edition of the WHO Classification of Tumors of the Central Nervous System (WHO CNS5), published in 2021, introduces major changes that advance the role of molecular diagnostics in meningiomas. To follow the revision of WHO CNS5, this expert consensus statement was formed jointly by the Group of Neuro-Oncology, Society of Neurosurgery, Chinese Medical Association together with neuropathologists and evidence-based experts. The consensus provides reference points to integrate key biomarkers into stratification and clinical decision making for meningioma patients.

Reference

[1]Elizabeth B, Claus,Peter J, Park,Rona, Carroll,etc.Specific genes expressed in association with progesterone receptors in meningioma.[J].2008,68.
[2]Andrés F,Cardona,Alejandro,Ruiz-Patiño,Zyanya Lucia,Zatarain-Barrón,etc.Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib.[J].2019,14(6).
[3]Hanemann, C. Oliver,Enki, Doyo G.,Shivane, Aditya,etc.Activation of multiple growth factor signalling pathways is frequent in meningiomas[J].2016,36(3).
[4]Louis David N.,Ohgaki Hiroko,Wiestler Otmar D.,etc.The 2007 WHO Classification of Tumours of the Central Nervous System[J].2007,114(2).
[5]Reardon,D.A.,Lou,E.,Sumrall,A.L.,etc.Bevacizumab therapy for adults with recurrent/progressive meningioma: A retrospective series[J].2012,109(1).
[6]Murillo, Miguel M.,Lopez-Lago, Miguel A.,Giancotti, Filippo G.,etc.Loss of the Tumor Suppressor Gene NF2, Encoding Merlin, Constitutively Activates Integrin-Dependent mTORC1 Signaling[J].2009,29(15).
[7]Michael, Sommerauer,Jan-Karl, Burkhardt,Karl, Frontzek,etc.68Gallium-DOTATATE PET in meningioma: A reliable predictor of tumor growth rate?[J].2016.
[8]Sahm,F.,Bissel,J.,Koelsche,C.,etc.AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry[J].2013,126(5).
[9]Nassiri Farshad,Liu Jeff,Patil Vikas,etc.A clinically applicable integrative molecular classification of meningiomas[J].2021,597(7874).
[10]Yuzawa, Sayaka,Nishihara, Hiroshi,Yamaguchi, Shigeru,etc.Clinical impact of targeted amplicon sequencing for meningioma as a practical clinical-sequencing system[J].2016,29(7).
[11]Peyre,M.,Stemmer-Rachamimov,A.,Clermont-Taranchon,E.,etc.Meningioma progression in mice triggered by Nf2 and Cdkn2ab inactivation[J].2013,32(36).
[12]Smith,M.J.,Wallace,A.J.,Bennett,C.,etc.Germline SMARCE1 mutations predispose to both spinal and cranial clear cell meningiomas[J].2014,234(4).
[13]C L, Maini,R, Sciuto,A, Tofani,etc.Somatostatin receptor imaging in CNS tumours using 111In-octreotide.[J].1995,16.
[14]Mittal Priya,Roberts Charles W. M..The SWI/SNF complex in cancer — biology, biomarkers and therapy[J].2020,17(7).
[15].Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysis[J].2020,91(4).
[16]Walter, Rachinger,Veit M, Stoecklein,Nicole A, Terpolilli,etc.Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue.[J].2015,56.
[17]Sievers, Philipp,Hielscher, Thomas,Schrimpf, Daniel,etc.CDKN2A/Bhomozygous deletion is associated with early recurrence in meningiomas[J].2020,140(3).
[18]Michael, Karsy,Mohammed A, Azab,Hussam, Abou-Al-Shaar,etc.Clinical potential of meningioma genomic insights: a practical review for neurosurgeons.[J].2018,44(6).
[19].Analysis of deletions in DNA from patients with Becker and Duchenne muscular dystrophy[J].1986,322(6074).
[20]Mark W,Youngblood,Daniel,Duran,Julio D,Montejo,etc.Correlations between genomic subgroup and clinical features in a cohort of more than 3000 meningiomas.[J].2019.
[21]Ivanidze Jana,Roytman Michelle,Lin Eaton,etc.Gallium‐68 DOTATATE PET in the Evaluation of Intracranial Meningiomas[J].2019,29(5).
[22]Concha Lopez-Gines,Miguel Cerda-Nicolas,Rosario Gil-Benso,etc.Association of loss of 1p and alterations of chromosome 14 in meningioma progression[J].2004,148(2).
[23]Wang,S.,Yang,W.,Deng,J.,etc.Correlation between 99mTc-HYNIC-octreotide SPECT/CT somatostatin receptor scintigraphy and pathological grading of meningioma[J].2013,113(3).
[24]David W. Kimmel,CaterinaGiannini,Derek R. Johnson,etc.Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma[J].2011,13(5).
[25]Ruth K Fredericks,Cathryn Rankin,Christy A Russell,etc.Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005.[J].2015,33(34).
[26]Holleczek, Bernd,Zampella, Daniel,Urbschat, Steffi,etc.Incidence, mortality and outcome of meningiomas: A population-based study from Germany[J].2019,62.
[27]Wolfgang K. Pfisterer,William P. Hendricks,Nicole C. Hank,etc.Diagnostic and prognostic significance of genetic regional heterogeneity in meningiomas[J].2004,6(4).
[28]B R, Seizinger,S, de la Monte,L, Atkins,etc.Molecular genetic approach to human meningioma: loss of genes on chromosome 22.[J].1987,84.
[29]Barresi, Valeria,Simbolo, Michele,Fioravanzo, Adele,etc.Molecular Profiling of 22 Primary Atypical Meningiomas Shows the Prognostic Significance of 18q Heterozygous Loss and CDKN2A/B Homozygous Deletion on Recurrence-Free Survival[J].2021,13(4).
[30]Gupta, Noopur,Chacko, Geeta,Chackol, Ari G.,etc.Fluorescence in situ hybridization for chromosome 14q deletion in subsets of meningioma segregated by MIB-1 labelling index[J].2016,64(6).
[31]Williams Erik A.,Santagata Sandro,Wakimoto Hiroaki,etc.Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic[J].2020,8(1).
[32]K, Lamszus,U, Lengler,N O, Schmidt,etc.Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy.[J].2000,46.
[33]Julien, Masliah-Planchon,Ivan, Bièche,Jean-Marc, Guinebretière,etc.SWI/SNF chromatin remodeling and human malignancies.[J].2015,10.
[34]Marc Remke,Vijay Ramaswamy,John Peacock,etc.TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma[J].2013,126(6).
[35]Ashraf, Fakhrjou,Ali, Meshkini,Sepideh, Shadrvan.Status of Ki-67, estrogen and progesterone receptors in various subtypes of intracranial meningiomas.[J].2012,15.
[36]Nakada, Satoko,Sasagawa, Yasuo,Tachibana, Osamu,etc.The clinicopathological analysis of receptor tyrosine kinases in meningiomas: the expression of VEGFR-2 in meningioma was associated with a higher WHO grade and shorter progression-free survival[J].2019,36(1).
[37]Aanchal, Kakkar,Anupam, Kumar,Amitabha, Das,etc.1p/14q co-deletion: A determinant of recurrence in histologically benign meningiomas.[J].1900,58.
[38]Abrey LE,Dancey J,Wen PY,etc.Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.[J].2010,96(2).
[39].Improved Detection of Transosseous Meningiomas Using 68Ga-DOTATATE PET-CT Compared to Contrast-Enhanced MRI.[J].2017,(Spec).
[40]Osorio, Diana S.,Hu, Jessica,Mitchell, Carole,etc.Effect of lapatinib on meningioma growth in adults with neurofibromatosis type 2[J].2018,139(3).
[41]Wenya Linda,Bi,Vikram C,Prabhu,Ian F,Dunn.anaplastic meningioma%atypical meningioma%genomics%high-grade meningioma%methylation%molecular classification%rhabdoid[J].2017,44(4).
[42]James, Marianne F.,Han, Sangyeul,Polizzano, Carolyn,etc.NF2/Merlin Is a Novel Negative Regulator of mTOR Complex 1, and Activation of mTORC1 Is Associated with Meningioma and Schwannoma Growth[J].2009,29(15).
[43]Gerhard,Jungwirth,Rolf,Warta,Christopher,Beynon,etc.Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT.[J].2019,7(1).
[44]Krayenbuhl N,Pravdenkova S,Al-Mefty O.De novo versus transformed atypical and anaplastic meningiomas: comparisons of clinical course, cytogenetics, cytokinetics, and outcome.[J].2007,61(3).
[45]Young Suk,Lee,Youn Soo,Lee.Molecular characteristics of meningiomas.[J].2020,54(1).
[46]Olar, Adriana,Wani, Khalida M.,Wilson, Charmaine D.,etc.Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma[J].2017,133(3).
[47]Pilar Gonzalez-Gomez,M.Josefa Bello,Dolores Arjona,etc.CpG island methylation of tumor-related genes in three primary central nervous system lymphomas in immunocompetent patients[J].2003,142(1).
[48]Graillon, Thomas,Sanson, Marc,Campello, Chantal,etc.Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial[J].2020,26(3).
[49]Waldemar Och,Tomasz Szmuda,Beata Sikorska,etc.Recurrence-associated chromosomal anomalies in meningiomas: Single-institution study and a systematic review with meta-analysis[J].2016,(6).
[50]Patrick Y. Wen.Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08)[J].2009,11(6).
[51]Miguel,T.S.,Gonzalez-Darder,J.,Cerda-Nicolas,M.,etc.Genetic changes with prognostic value in histologically benign meningiomas[J].2013,32(4).
[52]Kroger S,Tietje N,Mehdorn HM,etc.Somatostatin receptor scintigraphy in postsurgical follow-up examinations of meningioma.[J].1998,39(11).
[53]Williams, Sally R.,Juratli, Tareq A.,Castro, Brandyn A.,etc.Genomic Analysis of Posterior Fossa Meningioma Demonstrates Frequent AKT1 E17K Mutations in Foramen Magnum Meningiomas[J].2019,80(B6).
[54]Bertucci, Francois,Fekih, Mahmoud,Autret, Aurelie,etc.Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study[J].2016,17(5).
[55]A.Celal Iplikcioglu,Mustafa Aziz Hatiboglu,Erdinc Ozek,etc.Is progesteron receptor status really a prognostic factor for intracranial meningiomas?[J].2014,124.
[56]Cai Dan X.,Banerjee Ruma,Scheithauer Bernd W.,etc.Chromosome 1p and 14q FISH Analysis in Clinicopathologic Subsets of Meningioma: Diagnostic and prognostic Implications[J].2001.
[57]Wang,Y.,Marino-Enriquez,A.,Bennett,R.R.,etc.Dystrophin is a tumor suppressor in human cancers with myogenic programs[J].2014,46(6).
[58]Biczok, Annamaria,Kraus, Theo,Suchorska, Bogdana,etc.TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas[J].2018,139(3).
[59]Linsler, Stefan,Kraemer, Dennis,Driess, Christina,etc.Molecular Biological Determinations of Meningioma Progression and Recurrence.[J].2014,9(4).
[60]Inoue, Azusa,Jiang, Lan,Lu, Falong,etc.Maternal H3K27me3 controls DNA methylation-independent imprinting[J].2017,547(Jul.27 TN.7664).
[61]Sahm, Felix,Schrimpf, Daniel,Stichel, Damian,etc.DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis[J].2017,18(5).
[62]Abedalthagafi, Malak,Bi, Wenya Linda,Aizer, Ayal A.,etc.Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma[J].2016,18(5).
[63]G, Hildebrandt,K, Scheidhauer,C, Luyken,etc.High sensitivity of the in vivo detection of somatostatin receptors by 111indium (DTPA-octreotide)-scintigraphy in meningioma patients.[J].1994,126.
[64]Williams Erik A.,Wakimoto Hiroaki,Shankar Ganesh M.,etc.Frequent inactivating mutations of the PBAF complex gene PBRM1 in meningioma with papillary features[J].2020,140(1).
[65]FRoser,MNakamura,MBellinzona,etc.The prognostic value of progesterone receptor status in meningiomas[J].2004,57(10).
[66]Korhonen Katariina,Salminen Tiina,Raitanen Jani,etc.Female predominance in meningiomas can not be explained by differences in progesterone, estrogen, or androgen receptor expression[J].2006,80(1).
[67]C, Luyken,G, Hildebrandt,B, Krisch,etc.Clinical relevance of somatostatin receptor scintigraphy in patients with skull base tumours.[J].1996,65.
[68]Bi Wenya Linda,Greenwald Noah F.,Abedalthagafi Malak,etc.Genomic landscape of high-grade meningiomas[J].2017,2(1).
[69]David E Reuss,Rosario M Piro,David T W Jones,etc.Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations.[J].2013,125(3).
[70]Son Ki Young,Shin Dong Wook,Lee Ji Eun,etc.Association of metabolic syndrome with mobility in the older adults: a Korean nationwide representative cross-sectional study[J].2021,11(1).
[71]Eriks A,Lusis.Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma.[J].2005,65.
[72]Svetlana,Pravdenkova.Progesterone and estrogen receptors: opposing prognostic indicators in meningiomas.[J].2006,105.
[73]Nathoo N,Ugokwe K,Chang AS,etc.The role of 111indium-octreotide brain scintigraphy in the diagnosis of cranial, dural-based meningiomas.[J].2007,81(2).
[74]Alan A, Moazzam,Naveed, Wagle,Gabriel, Zada.Recent developments in chemotherapy for meningiomas: a review.[J].2013,35.
[75]Frexes-Steed M,Woodard A,Kim P,etc.Evidence for mitogen-associated protein kinase activation and transduction of mitogenic signals by platelet-derived growth factor in human meningioma cells.[J].2001,94(2).
[76]Nicolas, Marincek,Piotr, Radojewski,Rebecca A, Dumont,etc.Somatostatin receptor-targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long-term results of a phase II clinical trial.[J].2015,56.
[77]Brastianos,P.K.,Horowitz,P.M.,Santagata,S.,etc.Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations[J].2013,45(3).
[78]Franklin W, Huang,Eran, Hodis,Mary Jue, Xu,etc.Highly recurrent TERT promoter mutations in human melanoma.[J].2013,339.
[79]Sahm, Felix,Schrimpf, Daniel,Olar, Adriana,etc.TERT Promoter Mutations and Risk of Recurrence in Meningioma[J].2016,108(5).
[80]Camila Batista de Oliveira, Silva,Bárbara Roberta, Ongaratti,Geraldine, Trott,etc.Expression of somatostatin receptors (SSTR1-SSTR5) in meningiomas and its clinicopathological significance.[J].2015,8.
[81]Shankar, Ganesh M.,Santagata, Sandro.BAP1 mutations in high-grade meningioma: implications for patient care[J].2017,19(11).
[82]Victoria E, Clark,Akdes Serin, Harmanc?,Hanwen, Bai,etc.Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas.[J].2016.
[83]Goldbrunner, Roland,Minniti, Giuseppe,Preusser, Matthias,etc.EANO guidelines for the diagnosis and treatment of meningiomas[J].2016,17(9).
[84].Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors.[J].2017,8(1).
[85]Tsilou ET,Kim HJ,Asthagiri AR,etc.Neurofibromatosis type 2.[J].2009,373(9679).
[86]Grace,Collord,Patrick,Tarpey,Natalja,Kurbatova,etc.An integrated genomic analysis of anaplastic meningioma identifies prognostic molecular signatures.[J].2018,8(1).
[87]Plate,K.H.,Hassler,M.,Knosp,E.,etc.Microvascularization and expression of VEGF and its receptors in recurring meningiomas: Pathobiological data in favor of anti-angiogenic therapy approaches[J].2012,31(5).
[88]Suganth,Suppiah,Farshad,Nassiri,Wenya Linda,Bi,etc.Molecular and translational advances in meningiomas.[J].2019,21(Supplement_1).
[89]Grill, Jacques,Massimino, Maura,Bouffet, Eric,etc.Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma[J].2018,36(10).
[90]Cindy,Chau,Remco,van Doorn,Natasha M,van Poppelen,etc.Families with BAP1-Tumor Predisposition Syndrome in The Netherlands: Path to Identification and a Proposal for Genetic Screening Guidelines.[J].2019,11(8).
[91]Koelsche,C.,Sahm,F.,Capper,D.,etc.Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system[J].2013,126(6).
[92]Akash J,Patel,Ying-Wooi,Wan,Rami,Al-Ouran,etc.Molecular profiling predicts meningioma recurrence and reveals loss of DREAM complex repression in aggressive tumors.[J].2019,116(43).
[93]Baxter,D.S.,Orrego,A.,Rosenfeld,J.V.,etc.An audit of immunohistochemical marker patterns in meningioma[J].2014,21(3).
[94]Aysha,AlSahlawi,Rasha,Aljelaify,Amna,Magrashi,etc.New insights into the genomic landscape of meningiomas identified FGFR3 in a subset of patients with favorable prognoses.[J].2019,10(53).
[95]Pachow,D.,Andrae,N.,Kliese,N.,etc.MTORC1 inhibitors suppress meningioma growth in mouse models[J].2013,19(5).
[96]Deng Maximilian Y.,Sturm Dominik,Pfaff Elke,etc.Radiation-induced gliomas represent H3-/IDH-wild type pediatric gliomas with recurrent PDGFRA amplification and loss of CDKN2A/B[J].2021,12(1).
[97]Paramasivam, Nagarajan,Huebschmann, Daniel,Toprak, Umut H.,etc.Mutational patterns and regulatory networks in epigenetic subgroups of meningioma[J].2019,138(2).
[98]Katrin Lamszus,Lan Kluwe,Jakob Matschke,etc.Allelic Losses at 1p, 9q, 10q, 14q, and 22q in the Progression of Aggressive Meningiomas and Undifferentiated Meningeal Sarcomas[J].1999,110(2).
[99]Caltabiano,R.,Barbagallo,G.M.V.,Castaing,M.,etc.Prognostic value of EGFR expression in de novo and progressed atypical and anaplastic meningiomas: An immunohistochemical and fluorescence in situ hybridization pilot study[J].2013,57(2).
[100]José María Sayagués,María Dolores Tabernero,Ángel Maíllo.Alteraciones citogenéticas en meningiomas y su impacto en la evolución de la enfermedad[J].2007,128(6).
[101]Weller, Michael,Roth, Patrick,Sahm, Felix,etc.Durable Control of Metastatic AKT1-Mutant WHO Grade 1 Meningothelial Meningioma by the AKT Inhibitor, AZD5363[J].2017,109(3).
[102]Jesus Lomas,Cinthia Amiñoso,Pilar Gonzalez-Gomez,etc.Methylation status of TP73 in meningiomas[J].2004,148(2).
[103]Srovnal,J.,Sulla,I.,Vaverka,M.,etc.MEG3: A novel long noncoding potentially tumour-suppressing RNA in meningiomas[J].2013,112(1).
[104]J. Wendall Goodwin,John Crowley,Harmon J. Eyre,etc.A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a southwest oncology group study[J].1993,15(1).
[105]Brat, Daniel J.,Verhaak, Roel G. W.,Al-dape, Kenneth D.,etc.Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas[J].2015,372(26).
[106]Larson, Jon D.,Kasper, Lawryn H.,Paugh, Barbara S.,etc.Histone H3.3 K27M Accelerates Spontaneous Brainstem Glioma and Drives Restricted Changes in Bivalent Gene Expression[J].2019,35(1).
[107]Liu, Yu,Chen, Chong,Xu, Zhengmin,etc.Deletions linked to TP53 loss drive cancer through p53-independent mechanisms[J].2016,531(Mar.24 TN.7595).
[108]Norden, Andrew D.,Ligon, Keith L.,Hammond, Samantha N.,etc.Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma[J].2015,84(3).
[109]Hua, Lingyang,Zhu, Hongda,Li, Jingrun,etc.Prognostic value of estrogen receptor in WHO Grade III meningioma: a long-term follow-up study from a single institution[J].2018,128(6).
[110]Kaley, Thomas J.,Wen, Patrick,Schiff, David,etc.Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma[J].2015,17(1).
[111]Al-Mefty, Ossama,Ligon, Azra H.,Wen, Patrick Y.,etc.A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma[J].2016,18(2).
[112]Lu, Jian-Qiang,Reddy, Kesava.Letter: Familial Syndromes Involving Meningiomas Provide Mechanistic Insight Into Sporadic Disease[J].2019,85(2).
[113]Lindenberg, Kerstin,Schackert, Gabriele,Pietsch, Torsten,etc.DNA methylation-based classification of central nervous system tumours[J].2018,555(Mar.22 TN.7697).
[114]Goutagny,S.,Nault,J.C.,Mallet,M.,etc.High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression[J].2014,24(2).
[115]Juratli, Tareq A.,McCabe, Devin,Nayyar, Naema,etc.DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome[J].2018,136(5).
[116]Victoria E. Clark,E. Zeynep Erson-Omay,Akdes Serin,etc.Genomic Analysis of Non-NF2 Meningiomas Reveals Mutations in TRAF7, KLF4, AKT1, and SMO[J].2013,339(Mar.1 TN.6123).
[117]Katz, Leah M.,Hielscher, Thomas,Liechty, Benjamin,etc.Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence[J].2018,135(6).
[118].Treatment of unresectable skull base meningiomas with somatostatin analogs[J].2011,30(5).
[119]Pfisterer Wolfgang K.,Hendricks William P.,Scheck Adrienne C.,etc.Fluorescent in Situ Hybridization and Ex Vivo 1h Magnetic Resonance Spectroscopic Examinations of Meningioma Tumor Tissue[J].2007.
[120]Louis, David N.,Perry, Arie,Reifenberger, Guido,etc.The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary[J].2016,131(6).
[121]Markus J. Riemenschneider,Guido Reifenberger,Dimitri Barski,etc.Hypermethylation and Transcriptional Downregulation of the TIMP3 Gene is Associated with Allelic Loss on 22q12.3 and Malignancy in Meningiomas[J].2010,20(3).
[122].EGFR Soluble Isoforms and Their Transcripts Are Expressed in Meningiomas.[J].2012,7(5).
[123]Strazzullo V,Cappabianca P,De-Caro-Mdel B,etc.Recurrences of meningiomas: predictive value of pathological features and hormonal and growth factors.[J].2007,82(1).
[124]Rogers, C. Leland,Won, Minhee,Vogelbaum, Michael A.,etc.High-risk Meningioma: Initial Outcomes From NRG Oncology/RTOG 0539[J].2020,106(4).
[125]Yuzawa, Sayaka,Nishihara, Hiroshi,Tanaka, Shinya.Genetic landscape of meningioma[J].2016,33(4).
[126].The CREB-binding protein inhibitor ICG-001: a promising therapeutic strategy in sporadic meningioma with NF2 mutations[J].2020,2(1).
[127]Rembao D,Flores Estrada D,Martinez Rumayor A,etc.Angiogenesis and expression of estrogen and progesterone receptors as predictive factors for recurrence of meningioma.[J].2010,98(3).
[128]Jared Weiss.Bevacizumab in adjuvant treatment of non-small-cell lung cancer[J].2017,18(12).
[129]Santamarta D,Diaz P,Caballero M,etc.New classification scheme for the prognostic stratification of meningioma on the basis of chromosome 14 abnormalities, patient age, and tumor histopathology.[J].2003,21(17).
[130]M H, Ruttledge,J, Sarrazin,S, Rangaratnam,etc.Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas.[J].1994,6.
[131]NAGASAKA Toru.Fluorescent In Situ Hybridization 1p/19q Deletion/Imbalance Analysis of Low-Grade and Atypical Meningiomas[J].2010,50(1).
[132]Korner H,Epanchintsev A,Berking C,etc.Digital karyotyping reveals frequent inactivation of the dystrophin/DMD gene in malignant melanoma.[J].2007,6(2).
[133]Afshar-Oromieh Ali,Giesel Frederik L.,Linhart Heinz G.,etc.Detection of cranial meningiomas: comparison of 68Ga-DOTATOC PET/CT and contrast-enhanced MRI[J].2012,39(9).
[134]R, Wellenreuther,J A, Kraus,D, Lenartz,etc.Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma.[J].1995,146.
[135]Bello M. Josefa,Amiñoso Cinthia,Lopez-Marin Isabel,etc.DNA methylation of multiple promoter-associated CpG islands in meningiomas: relationship with the allelic status at 1p and 22q[J].2004,108(5).
[136]Shih, Kent C.,Chowdhary, Sajeel,Rosenblatt, Paul,etc.A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma[J].2016,129(2).
[137]Nagashima Goro,Asai Jun-ichirou,Suzuki Ryuta,etc.Different distribution of c-myc and MIB-1 positive cells in malignant meningiomas with reference to TGFs, PDGF, and PgR expression[J].2001,18(1).
[138]K H, Bohuslavizki,W, Brenner,W E, Braunsdorf,etc.Somatostatin receptor scintigraphy in the differential diagnosis of meningioma.[J].1996,17.
[139]Dittmar Jan Oliver,Kratochwil Clemens,Dittmar Anne,etc.First intraindividual comparison of contrast-enhanced MRI, FET- and DOTATOC- PET in patients with intracranial meningiomas[J].2017,12(1).
[140]Paul Kleihues,Peter C. Burger,Bernd W. Scheithauer.The New WHO Classification of Brain Tumours[J].1993,3(3).
[141]Bleeker F E,Felicioni L,Buttitta F,etc.AKT1E17K in human solid tumours[J].2008,27(42).
[142]R G, Weber,J, Bostr?m,M, Wolter,etc.Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression.[J].1997,94.
[143]Hoxhaj Gerta,Manning Brendan D..The PI3K–AKT network at the interface of oncogenic signalling and cancer metabolism[J].2019,20(2).
[144]Anne Guyot,Mathilde Duchesne,Srine Robert,etc.Analysis of CDKN2A gene alterations in recurrent and non-recurrent meningioma[J].2019,145(3).
[145]Ferrara Napoleone,Hillan Kenneth J.,Gerber Hans-Peter,etc.Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer[J].2004,3(5).
[146]M, Henze,J, Schuhmacher,P, Hipp,etc.PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas.[J].2001,42.
[147]Barbara, Gehler,Frank, Paulsen,Mehmet O, Oksüz,etc.[68Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planning.[J].2009,4.
[148]DuPlessis,D.,Smith,M.J.,Fitzpatrick,D.,etc.Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas[J].2013,45(3).
[149]Shankar, Ganesh M.,Abedalthagafi, Malak,Vaubel, Rachael A.,etc.Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas[J].2017,19(4).
[150]Nakane Y,Natsume A,Wakabayashi T,etc.Malignant transformation-related genes in meningiomas: allelic loss on 1p36 and methylation status of p73 and RASSF1A.[J].2007,107(2).
[151]Sievers, Philipp,Sill, Martin,Blume, Christina,etc.Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1[J].2021,141(2).
[152]Ignacio Varela,Patrick Tarpey,Keiran Raine,etc.Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma[J].2011,469(Jan.27 TN.7331).
[153]Arbajian, Elsa,Puls, Florian,Antonescu, Cristina R.,etc.In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets[J].2017,23(23).
[154]G\u00fcliz Acker,"name":"2Berlin Institute of Health (BIH), Berlin, Germany,and",etc.Impact of 68Ga-DOTATOC PET\/MRI on robotic radiosurgery treatment planning in meningioma patients: first experiences in a single institution[J].2019,46(6).
[155]Krug, Brian,De Jay, Nicolas,Harutyunyan, Ashot S.,etc.Pervasive H3K27 Acetylation Leads to ERV Expression and a Therapeutic Vulnerability in H3K27M Gliomas[J].2019,35(5).